SAC Capital Advisors loaded up on shares of InterMune, a pharmaceutical company, when it looked like the company’s hotly anticipated new drug would get approval from the Food and Drug Administration.
To continue reading,
subscribe now
to Premium Journalism. Already a subscriber? login.
